PTPN3 Is a Potential Target for a New Cancer Immunotherapy That Has a Dual Effect of T Cell Activation and Direct Cancer Inhibition in Lung Neuroendocrine Tumor

Experiments in a mouse xenograft model using allo lymphocytes showed that PTPN3 inhibition in small cell lung cancer cells enhanced the anti-tumor effect of phosphatase non-receptor type 3 (PTPN3)-suppressed activated lymphocytes.